Immediate Impact
68 standout
Citing Papers
An empowerment model for managing menopause
2024 Standout
Understanding and targeting resistance mechanisms in cancer
2023 Standout
Works of Ermanno Rondini being referenced
Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.
2012
Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer
2012
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Ermanno Rondini | 175 | 123 | 135 | 32 | 381 | |
| Gil Facina | 184 | 36 | 99 | 54 | 432 | |
| Rui Liu | 163 | 100 | 58 | 41 | 437 | |
| Afonso Celso Pinto Nazário | 163 | 38 | 108 | 55 | 404 | |
| Jian Tang | 116 | 71 | 76 | 21 | 371 | |
| Dorota Łubgan | 111 | 53 | 27 | 23 | 343 | |
| Norman Galbraith | 72 | 40 | 174 | 29 | 439 | |
| Jun He | 113 | 48 | 66 | 25 | 435 | |
| Mai‐Yee Luk | 219 | 103 | 70 | 28 | 440 | |
| Takashi Kuwayama | 111 | 63 | 73 | 31 | 399 | |
| Qiyu Liu | 104 | 99 | 32 | 50 | 432 |
All Works
Login with ORCID to disown or claim papers
Loading papers...